Clementi, L.; Poggialini, F.; Musumeci, F.; Taglienti, J.; Cornacchia, E.; Vagaggini, C.; Carbone, A.; Grossi, G.; Dreassi, E.; Angelucci, A.;
et al. Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma Treatment. Pharmaceutics 2025, 17, 704.
https://doi.org/10.3390/pharmaceutics17060704
AMA Style
Clementi L, Poggialini F, Musumeci F, Taglienti J, Cornacchia E, Vagaggini C, Carbone A, Grossi G, Dreassi E, Angelucci A,
et al. Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma Treatment. Pharmaceutics. 2025; 17(6):704.
https://doi.org/10.3390/pharmaceutics17060704
Chicago/Turabian Style
Clementi, Letizia, Federica Poggialini, Francesca Musumeci, Julia Taglienti, Emanuele Cornacchia, Chiara Vagaggini, Anna Carbone, Giancarlo Grossi, Elena Dreassi, Adriano Angelucci,
and et al. 2025. "Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma Treatment" Pharmaceutics 17, no. 6: 704.
https://doi.org/10.3390/pharmaceutics17060704
APA Style
Clementi, L., Poggialini, F., Musumeci, F., Taglienti, J., Cornacchia, E., Vagaggini, C., Carbone, A., Grossi, G., Dreassi, E., Angelucci, A., & Schenone, S.
(2025). Evaluation of Antitumoral Activity in a 3D Cell Model of a Src Inhibitor Prodrug for Glioblastoma Treatment. Pharmaceutics, 17(6), 704.
https://doi.org/10.3390/pharmaceutics17060704
